Asthma Clinical Trial
Official title:
A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)
Primary objective of the study is to evaluate whether patients with severe eosinophilic
asthma who have received long-term treatment with mepolizumab (at least 3 years) need to
maintain treatment with mepolizumab to continue to receive benefit. Subjects who participated
in the open-label studies MEA115666 or 201312 with at least 6 months of treatment with
mepolizumab prior to Visit 1 and who have no more than 2 consecutive missed doses of
mepolizumab treatment will be eligible to participate in this study. This study will be
conducted in 4 parts in approximately 300 subjects. Part A will be Variable Open-Label Run-in
(for subjects with less than 3 years of mepolizumab treatment). Once the required 3 year
exposure is reached, subjects will enter Part B- Fixed Open-Label Run-In (4 weeks to 8
weeks). During Part A and B subjects will be administered Open-label mepolizumab (100
milligram [mg] Subcutaneous [SC]) every 4 weeks. Part C will be the randomized double-blinded
part. Upon completion of Part B, eligible subjects will be randomized to mepolizumab (100 mg
SC) every 4 weeks or placebo administered SC every 4 weeks for 52 weeks.
Subjects discontinuing investigational product (IP) due to a clinically significant asthma
exacerbation will then enter optional Part D of the study. During Part D, subjects receive
open-label mepolizumab in addition to their standard of care therapy for the remainder of the
study, through Part D up to 52-weeks post-randomization. An Exit Visit will be conducted 52
weeks after randomization in order to assess subject's efficacy parameters, immunogenicity
status, and to conduct additional safety assessments. Eligible subjects will participate in
the study ranging from 56 to192 weeks, depending on the duration of Part A (0 to 132 weeks)
and Part B (4 to 8 weeks).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|